May 7, 2020 / 11:18 AM / a month ago

BRIEF-Teva Reports Q1 Non-GAAP Earnings Per Share $0.76

May 7 (Reuters) - Teva Pharmaceutical Industries Ltd :

* TEVA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

* Q1 NON-GAAP EARNINGS PER SHARE $0.76

* FULL YEAR 2020 BUSINESS OUTLOOK REAFFIRMED

* REVENUES FROM NORTH AMERICA SEGMENT IN Q1 OF 2020 WERE $2,082 MILLION, AN INCREASE OF $36 MILLION

* GENERIC PRODUCTS REVENUES IN OUR NORTH AMERICA SEGMENT IN Q1 WERE $952 MILLION, DOWN 1% COMPARED TO Q1 2019

* COPAXONE REVENUES IN NORTH AMERICA SEGMENT IN Q1 OF 2020 DECREASED BY 5% TO $198 MILLION, COMPARED TO Q1 OF 2019

* GENERIC PRODUCTS REVENUE IN NORTH AMERICA SEGMENT IN QUARTER DOWN 1% TO $952 MILLION

* COPAXONE REVENUE IN NORTH AMERICA IN QUARTER DOWN 5% AT $198 MILLION

* AUSTEDO REVENUES IN N. AMERICA SEGMENT IN Q1 INCREASED BY 64% TO $122 MILLION, COMPARED TO $74 MILLION IN Q1 OF 2019

* AS OF MARCH 31, 2020, OUR DEBT WAS $26,103 MILLION, COMPARED TO $26,908 MILLION AS OF DECEMBER 31, 2019

* TEVA PHARMACEUTICAL- DECREASE IN DEBT WAS MAINLY DUE TO REPAYMENT AT MATURITY OF $700 MILLION 2.25% SENIOR NOTE SENIOR NOTES, EXCHANGE RATE FLUCTUATIONS

* IMPAIRMENT OF LONG-LIVED ASSETS OF $724 MILLION IN QUARTER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below